Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $2.50 USD
Change Today +0.03 / 1.21%
Volume 443.2K
AMPE On Other Exchanges
As of 8:04 PM 05/4/15 All times are local (Market data is delayed by at least 15 minutes).

ampio pharmaceuticals inc (AMPE) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/18/15 - $9.01
52 Week Low
05/1/15 - $2.35
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

ampio pharmaceuticals inc (AMPE) Related Businessweek News

No Related Businessweek News Found

ampio pharmaceuticals inc (AMPE) Details

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing therapies for the treatment of prevalent inflammatory conditions in the United States. The company is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depletion of the available phosphate needed for the inflammation process; and decreasing vascular permeability. Its lead product candidates in development include Ampion, which is in Phase III clinical trial for osteoarthritis of the knee; and Optina that is in Phase IIb clinical trial for diabetic macular edema. Ampio Pharmaceuticals, Inc. is headquartered in Englewood, Colorado.

23 Employees
Last Reported Date: 02/24/15

ampio pharmaceuticals inc (AMPE) Top Compensated Officers

Founder, Chairman and Chief Executive Officer
Total Annual Compensation: $455.0K
Chief Financial Officer, Corporate Secretary ...
Total Annual Compensation: $143.5K
Chief Regulatory Affairs Officer
Total Annual Compensation: $255.0K
Chief Scientific Officer and Director
Total Annual Compensation: $305.0K
Compensation as of Fiscal Year 2014.

ampio pharmaceuticals inc (AMPE) Key Developments

Ampio Pharmaceuticals, Inc. Announces Resignation of Joshua R. Disbrow as Chief Operating Officer

On April 16, 2015, Joshua R. Disbrow resigned as Chief Operating Officer of Ampio Pharmaceuticals, Inc. in connection with the Merger (as defined below) to assume the role of Chief Executive Officer of Rosewind. On April 16, 2015, Luoxis Diagnostics, Inc. and Vyrix, each previously a subsidiary of Ampio, entered into an agreement and plan of merger by and among Rosewind, Luoxis, Vyrix, two major stockholders of Rosewind and two subsidiaries of Rosewind created solely for the purposes of the merger.

Ampio Pharmaceuticals, Inc. - Shareholder/Analyst Call

Ampio Pharmaceuticals, Inc. - Shareholder/Analyst Call

Ampio Pharmaceuticals, Inc. Announces Ampion™ STRIDE Study Results

Ampio Pharmaceuticals, Inc. announced that the multiple injection STRIDE study AP008 did not reach its primary endpoint against the saline control even though there was a statistically significant reduction in pain compared to baseline for patients receiving Ampion™ (WOMAC A: p < 0.001). This pain reduction with Ampion™ was consistent across all sites and with previously reported studies (SPRING and STRUT). Ampion™ is safe and well tolerated. Ampio Pharmaceuticals launched the Phase III program for AmpionTM " a low molecular weight filtrate of an FDA approved biologic " to treat pain due to osteoarthritis (OA) of the knee. Each patient received three 4ml intra-articular injections of Ampion™or the saline placebo, one at baseline, the second at two weeks and the third at four weeks. In OA, saline is known to be a partial therapeutic and not a true placebo, but has been the control used in all published OA drug trials. In the STRIDE study the saline control arm varied well out of a normal range, when compared to previous Ampion™ studies and from the published results for other OA drugs. In the STRIDE study, the percentage change in WOMAC A for the saline control arm ranged from 12% to 60% from site to site. This is more than twice the range have previously seen in studies. Historically, in larger studies, the response to saline has been reported to be in a range of 30-35%. In addition, the company is analyzing the demographic differences between the patient populations in the STRIDE study compared to the SPRING and STRUT studies. Disease Severity: 68% of subjects in the STRIDE study had severe disease (Kellgren-Lawrence 4) versus 38% in the STRUT study and 23% in the SPRING study; Weight: Patients in the STRIDE study were significantly heavier than patients in the STRUT study or other published trials.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AMPE:US $2.50 USD +0.03

AMPE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AMPE.
View Industry Companies

Industry Analysis


Industry Average

Valuation AMPE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1,672.3x
Price/Book 1.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1,025.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AMPIO PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at